A comprehensive, evidence-based guide to the side effects associated with GLP-1 receptor agonist medications — including both FDA-approved brand-name drugs and compounded alternatives. Understanding the risks is essential to making an informed treatment decision.
Important: This page is for informational purposes only and does not constitute medical advice. Side effects vary by individual, dose, and medication. Always discuss risks and benefits with your licensed healthcare provider before starting, stopping, or changing any medication.
Common Side Effects (FDA-Approved Medications)
The following side effects are documented in FDA prescribing labels for semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound, Mounjaro). Most are gastrointestinal in nature and tend to be most pronounced during dose escalation — typically improving within 4-8 weeks as the body adjusts.
Gastrointestinal (Most Common)
Nausea — Reported by 20-44% of patients in clinical trials. The most frequently cited side effect across all GLP-1 medications. Usually dose-dependent and often improves with time.
Diarrhea — Affects 15-30% of patients. Can lead to dehydration if severe — patients should maintain adequate fluid intake.
Vomiting — Occurs in 6-25% of patients, more common during dose increases. Can be managed by eating smaller meals.
Constipation — Reported by 10-24% of patients. GLP-1s slow gastric emptying, which can affect bowel regularity.
Abdominal pain — Stomach discomfort, cramping, and bloating affect 5-20% of patients across GLP-1 classes.
Other Common Effects
Decreased appetite — This is both a therapeutic effect and a side effect. While desired for weight loss, it can lead to nutritional deficiencies if not managed properly.
Headache — Reported by 10-14% of patients, typically mild and transient.
Fatigue and dizziness — Reduced caloric intake combined with medication effects can cause tiredness, especially in the first weeks.
Injection site reactions — Redness, swelling, or itching at the injection site. Usually mild and temporary.
Heartburn (GERD) — Acid reflux and indigestion, reported in 5-12% of patients.
Belching and gas — Particularly noted with tirzepatide (Zepbound/Mounjaro).
Serious Side Effects and Warnings
The following side effects are less common but medically significant. FDA prescribing labels carry boxed warnings or specific cautions for these conditions. Patients should be aware of the symptoms and seek medical attention promptly if they occur.
In animal studies, both semaglutide and tirzepatide caused dose-dependent thyroid C-cell tumors at clinically relevant exposures. While it is unknown whether GLP-1 medications cause thyroid tumors in humans, the FDA requires a boxed warning — the most serious type of warning. GLP-1 medications are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Patients should report any lump or swelling in the neck, difficulty swallowing, or persistent hoarseness.
Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists. Symptoms include severe abdominal pain that may radiate to the back, often accompanied by vomiting. If pancreatitis is suspected, the medication should be discontinued immediately and not restarted. Patients with a history of pancreatitis face elevated risk.
GLP-1 medications are associated with increased risk of cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation). Rapid weight loss is a known risk factor for gallstones. In Zepbound clinical trials, gallbladder-related events occurred in approximately 1.7% of patients versus 0.5% on placebo. Symptoms include sudden, intense pain in the upper-right abdomen, nausea, and fever.
Postmarketing reports document cases of acute kidney injury, some requiring hemodialysis, in patients taking semaglutide. The majority of cases occurred in patients experiencing severe gastrointestinal side effects (nausea, vomiting, diarrhea) leading to dehydration. Patients should maintain adequate hydration, especially during dose escalation when GI symptoms are most likely.
GLP-1 medications slow gastric emptying by design — that’s part of how they suppress appetite. In some patients, this effect becomes pathological, leading to gastroparesis: severely delayed stomach emptying that causes persistent nausea, vomiting, bloating, and abdominal pain. Studies suggest rates below 2%, and the condition typically improves after discontinuing the medication or reducing the dose. However, this is a key consideration for patients undergoing surgery requiring general anesthesia, as residual stomach contents can cause pulmonary aspiration.
While GLP-1s are less likely to cause hypoglycemia than insulin, the risk increases significantly when combined with sulfonylureas or insulin. Patients with type 2 diabetes on combination therapy should monitor blood sugar carefully and may need dose adjustments to other diabetes medications.
Semaglutide (Ozempic, Wegovy) carries a specific warning for worsening of diabetic retinopathy in patients with type 2 diabetes and existing eye disease. Rapid improvement in blood sugar control can paradoxically worsen retinopathy. Patients with a history of diabetic eye disease should have regular ophthalmologic monitoring.
Emerging and Long-Term Concerns
As GLP-1 medications have been in widespread use for weight loss since approximately 2021, the long-term safety profile is still being established. The following concerns are based on postmarketing surveillance, observational studies, and ongoing clinical research.
Hair Loss
Hair thinning or loss (telogen effluvium) has been reported by GLP-1 users, particularly during rapid weight loss. This is not unique to GLP-1 medications — it occurs with any significant caloric deficit and typically resolves 3-6 months after weight stabilizes. Tirzepatide clinical trials reported hair loss in approximately 5% of participants on higher doses.
Muscle Mass Loss
A portion of weight lost on GLP-1 medications is lean muscle mass — studies suggest 25-40% of total weight loss may come from lean tissue rather than fat. This has implications for metabolic rate, physical function, and long-term weight maintenance. Resistance exercise and adequate protein intake are critical during GLP-1 treatment.
Bone Density
Rapid weight loss from any cause can reduce bone mineral density. GLP-1 medications may additionally affect calcium absorption by slowing gastric emptying. Early research suggests potential concerns about osteoporosis risk, particularly in postmenopausal women and older adults. More long-term data is needed.
Mental Health
The FDA requires monitoring for suicidal ideation and depression in GLP-1 patients. However, large-scale studies have been reassuring: a nationwide retrospective analysis found no elevated risk of suicidality compared to other diabetes medications, and many studies show improvement in depressive symptoms. Weight loss itself can have complex psychological effects.
Additional Risks: Compounded GLP-1 Medications
Compounded versions of semaglutide and tirzepatide are not FDA-approved and carry unique risks beyond the side effects of the active ingredients themselves. While legally permitted when the brand-name drug is on the FDA shortage list, compounded medications do not undergo the same rigorous safety, efficacy, and quality reviews as FDA-approved drugs.
The FDA has received reports of patients accidentally self-administering 5 to 20 times the intended dose of compounded semaglutide. Unlike pre-filled brand-name pens that deliver exact doses, compounded vials require patients to measure doses with syringes — a process prone to error. Overdose symptoms include severe nausea, vomiting, hypoglycemia, and in extreme cases, hospitalization.
Compounding pharmacies may use semaglutide sodium or semaglutide acetate — salt forms that are chemically different from the semaglutide base used in Ozempic and Wegovy. The FDA has stated these are different active ingredients that have not been independently studied for safety and efficacy in clinical trials. The bioavailability, absorption rate, and side effect profile may differ from the approved formulation.
Injectable medications require strict sterile manufacturing conditions. While FDA-registered 503B outsourcing facilities operate under cGMP standards, many compounding pharmacies operate under less rigorous state-level oversight. The FDA has documented cases of contamination, incorrect potency, and substandard sterility in compounded injectables. For a medication injected subcutaneously, contamination can cause serious infections.
As of 2026, the FDA has issued over 55 warning letters to online sellers of compounded GLP-1 products and is actively taking steps to restrict compounding of semaglutide and tirzepatide. The regulatory landscape is changing rapidly — patients currently using compounded GLP-1s should be aware that availability may be disrupted and should have a contingency plan with their healthcare provider.
As of April 2025, the FDA had received 520 adverse event reports for compounded semaglutide and 480 for compounded tirzepatide. Reported events include severe gastrointestinal issues, fainting, dehydration, pancreatitis, and gallstones requiring hospitalization. While the actual incidence rate is unknown (since reporting is voluntary), the volume of reports is noteworthy for non-FDA-approved products.
Side Effects by Medication
| Side Effect | Semaglutide (Ozempic, Wegovy) |
Tirzepatide (Zepbound, Mounjaro) |
Liraglutide (Saxenda) |
Compounded (Semaglutide/Tirzepatide) |
|---|---|---|---|---|
| Nausea | 20-44% | 12-33% | 39% | Similar + dosing risk |
| Diarrhea | 15-30% | 12-25% | 21% | Similar + dosing risk |
| Vomiting | 6-24% | 5-13% | 16% | Similar + dosing risk |
| Hair loss | ~3% | ~5% | Rare | Unknown |
| Pancreatitis | Rare (<1%) | ~0.2% | Rare | Unknown (not studied) |
| Gallbladder events | 1.6% | 1.7% | 2.5% | Unknown |
| Dosing error risk | Low (pre-filled pen) | Low (pre-filled pen) | Low (pre-filled pen) | HIGH (vial + syringe) |
Sources: FDA prescribing labels for Ozempic, Wegovy, Zepbound, Mounjaro, and Saxenda; FDA adverse event reports for compounded products. Rates are approximate ranges from clinical trial data.
What Patients Should Do
Before Starting
Discuss your full medical history, including any thyroid conditions, history of pancreatitis, gallbladder disease, or kidney problems. Inform your provider of all medications you take, especially diabetes drugs.
During Treatment
Stay hydrated — dehydration from GI side effects is the most common pathway to serious complications. Eat smaller meals. Engage in resistance exercise to preserve muscle mass. Report persistent or severe symptoms promptly.
If Using Compounded
Ask your provider about the compounding pharmacy’s accreditation (503B vs. 503A). Request a Certificate of Analysis (CoA). Double-check dosing instructions carefully. Have a contingency plan if compounded supply is disrupted.
When to Seek Help
Seek immediate medical attention for: severe abdominal pain (pancreatitis), persistent vomiting or inability to keep fluids down (dehydration/kidney risk), a lump in your neck (thyroid), or signs of allergic reaction (swelling, difficulty breathing).
Find a Provider You Can Trust
Our independently scored directory helps you compare GLP-1 providers based on clinical quality, safety, and trust — not affiliate commissions.
Sources: FDA prescribing labels for Ozempic, Wegovy, Zepbound, Mounjaro, and Saxenda; FDA postmarket safety communications; JAMA Network studies on GI adverse events; PMC research on gastroparesis, mental health, and bone density; FDA warning letters to compounded GLP-1 sellers (2025-2026).
Last Updated: April 2026. This page is reviewed and updated as new safety data becomes available.
